CSBio CSBio

X
[{"orgOrder":0,"company":"Anova Pharma","sponsor":"NeOnc Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anova Partners with NeOnc Technologies to Bring NEO100 to Patients With IDH1 Mutated Gliomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"VIETNAM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Anova Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            As part of the partnership, Anova will support patient identification and access to NEO100 clinical trials, and when clinical trials are not an option for patients with IDH1 mutated Glioma, early access for compassionate use will be supported.

            Lead Product(s): Perillyl Alcohol

            Therapeutic Area: Oncology Product Name: NEO100

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: NeOnc Technologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 29, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY